Join

Compare · HYPR vs LIVN

HYPR vs LIVN

Side-by-side comparison of Hyperfine Inc. (HYPR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HYPR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • LIVN is the larger of the two at $4.11B, about 29.4x HYPR ($140.0M).
  • Over the past year, HYPR is up 79.9% and LIVN is up 61.5% - HYPR leads by 18.4 points.
  • HYPR has been more active in the news (11 items in the past 4 weeks vs 5 for LIVN).
  • LIVN has more recent analyst coverage (20 ratings vs 4 for HYPR).
PerformanceHYPR+79.90%LIVN+61.48%
2025-06-09+0.00%2026-06-08
MetricHYPRLIVN
Company
Hyperfine Inc.
LivaNova PLC
Price
$1.41+0.36%
$74.83+3.48%
Market cap
$140.0M
$4.11B
1M return
-16.86%
+5.57%
1Y return
+79.90%
+61.48%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2021
News (4w)
11
5
Recent ratings
4
20
HYPR

Hyperfine Inc.

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

LIVN

LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Latest HYPR

Latest LIVN